Global Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) Pipeline Review 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016" report to their offering.

"Leber's Hereditary Optic Neuropathy - Pipeline Review, H2 2016": Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline therapeutics constitutes close to 11 molecules, out of which approximately 10 molecules are developed by Companies and the remaining by the Universities/Institutes.

Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties; rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer-treating drugs, stress-related chemicals, some antibiotics and cyanogens.

"Leber's Hereditary Optic Neuropathy - Pipeline Review, H2 2016" outlays comprehensive information on the therapeutics under development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by Companies/Universities.

It also reviews key players involved in therapeutic development for Leber's Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects. Currently, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 3, 1 and 1, respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecule, respectively.

Key Topics Covered:

  1. Introduction
  2. Leber's Hereditary Optic Neuropathy Leber optic atrophy Overview
  3. Therapeutics Development
  4. Pipeline Products for Leber's Hereditary Optic Neuropathy Leber optic atrophy - Overview
  5. Pipeline Products for Leber's Hereditary Optic Neuropathy Leber optic atrophy - Comparative Analysis
  6. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Therapeutics under Development by Companies
  7. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Therapeutics under Investigation by Universities/Institutes
  8. Leber's Hereditary Optic Neuropathy Leber optic atrophy Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Products under Development by Companies
  13. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Products under Investigation by Universities/Institutes
  14. Leber's Hereditary Optic Neuropathy Leber optic atrophy - Companies Involved in Therapeutics Development
  • Alkeus Pharmaceuticals Inc.
  • Biovista Inc.
  • GenSight Biologics S.A.
  • Ixchel Pharma LLC
  • Khondrion BV
  • Spark Therapeutics Inc.
  • Stealth BioTherapeutics Inc.

For more information about this report visit http://www.researchandmarkets.com/research/p8z6vk/lebers.

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs